Harmony Biosciences (HRMY) Stock
Commercial drug company focused on narcolepsy treatments. Here's the price, business snapshot, and what's worth knowing about Harmony Biosciences in August 2026.
Harmony Biosciences Holdings Inc (HRMY) is a commercial-stage biopharmaceutical company focused on treatments for rare central nervous system sleep disorders, principally narcolepsy. Its lead product, WAKIX (pitolisant), is approved in the US for excessive daytime sleepiness and cataplexy in adults with narcolepsy and is the primary revenue driver. Investors should note the company’s growth depends on product uptake, label expansions, and successful commercial execution, while research and development and regulatory outcomes can materially affect prospects. With a market capitalisation near $1.5 billion, Harmony sits in the small-to-mid cap range where volatility can be higher than larger drugmakers. The company currently does not pay a dividend and invests earnings into marketing and development. Potential upside stems from increased market penetration, international launches and pipeline progress; downsides include competition, pricing pressures, reimbursement challenges and clinical or regulatory setbacks. This summary is for educational purposes only and not personalised investment advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Harmony Biosciences stock, expecting it to rise to $46.5.
Financial Health
Harmony Biosciences is showing strong revenue and profits, supported by healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Lead Product Focus
WAKIX is the company’s primary revenue engine and regulatory successes or label expansions could be meaningful, though performance can vary and competition exists.
Commercial Growth Angle
Sales growth depends on clinician adoption, patient awareness and reimbursement; these commercial levers offer upside but also bring execution risk.
Expansion Opportunities
International launches and pipeline progress could diversify revenue streams, but regulatory and market access hurdles may limit near-term impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
